SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that it has entered into a license agreement with Advanced BioScience Laboratories, Inc. (ABL) so that ABL may provide advanced electroporation delivery of DNA vaccines for its research uses. The license will permit ABL, based in Kensington, Maryland, to conduct certain internal research on DNA vaccines delivered using electroporation and to offer electroporation delivery of DNA vaccines as a service for its research customers. Inovio will receive a royalty on such services.
